Dolutegravir-induced neural tube defects in mice are folate responsive.

ABSTRACT:

Objectives

In 2018, the Botswana Tsepamo Study reported a nine-fold increased risk of neural tube defects in infants whose mothers were treated with dolutegravir (DTG) from the time of conception. As maternal folate supplementation and status is a well known modifier of neural tube defect (NTD) risk, we sought to evaluate birth outcomes in mice fed normal and low folic acid diets treated with DTG during pregnancy.

Design

DTG was evaluated for developmental toxicity using pregnant mice fed normal or low folic acid diet.

Methods

CD-1 mice were provided diet with normal (3 mg/kg) or low (0.3 mg/kg) folic acid. They were treated with water, a human therapeutic-equivalent dose, or supratherapeutic dose of DTG from mouse embryonic day E6.5 to E12.5. Pregnant dams were sacri

SUBMITTER: Tukeman GL 

PROVIDER: S-EPMC10755062 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature